DES

Desmin is a muscle-specific type III intermediate filament protein that assembles into 10-nm filaments through its coiled-coil rod domain, forming the cytoskeletal network that links Z-discs, desmosomes, and the extracellular matrix in striated and smooth muscle. An intact rod domain—particularly the 1A and 2B segments—is essential for proper filament polymerization; pathogenic missense mutations and in-frame deletions in these segments abolish filament assembly in vitro and exert dominant-negative effects on wild-type desmin networks, causing cytoplasmic aggregate formation (PMID:9736733, PMID:17325244, PMID:30908796). Desmin interacts directly with desmoplakin at desmosomes and with desmuslin/α-dystrobrevin at the Z-disc–extracellular matrix interface, and its function is modulated by PKA phosphorylation compartmentalized through PDE4DIP (PMID:9261168, PMID:11353857, PMID:34289528). Mutations in DES cause a spectrum of desmin-related myopathies and cardiomyopathies—including dilated, restrictive, arrhythmogenic right ventricular, and left-ventricular non-compaction cardiomyopathies—as well as skeletal myopathy and conduction disease (PMID:9697706, PMID:20829228, PMID:34680517).

1. 1990 High

   Identification of desmin as a substrate of HIV-1 protease established that targeted cleavage of intermediate filaments can collapse the IF cytoskeleton, demonstrating the structural vulnerability of the desmin network to proteolytic disruption.

   Evidence In vitro protease cleavage with microsequencing of the Leu-422/Arg-423 site; microinjection of HIV-1 protease into fibroblasts with immunofluorescence

   PMID:2201025

   Open questions at the time

   • Physiological relevance of HIV-1 protease cleavage of desmin in infected muscle tissue not established
   • No endogenous muscle protease shown to cleave desmin at this site
2. 1997 Medium

   Demonstration that desmoplakin's C-terminal domain directly binds desmin revealed the molecular mechanism by which desmosomes anchor the intermediate filament cytoskeleton to cell–cell junctions in muscle.

   Evidence Yeast two-hybrid and in vitro dot blot binding assays

   PMID:9261168

   Open questions at the time

   • Interaction not validated by co-immunoprecipitation or in vivo crosslinking
   • Binding affinity and stoichiometry not determined
   • Specificity relative to other type III IFs not fully resolved
3. 1998 High

   The parallel discoveries that DES rod-domain mutations cause familial cardioskeletal myopathy and that rod-domain deletions abolish 10-nm filament assembly in vitro established DES as a disease gene and demonstrated that pathogenic mutations act through loss of filament polymerization.

   Evidence Genetic sequencing of two independent families; recombinant desmin expression with in vitro filament assembly assays and cell transfection

   PMID:9697706 PMID:9736733

   Open questions at the time

   • Mechanism of cytoplasmic aggregate toxicity (gain-of-function vs. loss-of-function) not resolved
   • Animal models not yet reported at this stage
4. 2001 High

   Discovery of desmuslin as a direct desmin-binding partner at Z-lines, linking desmin to α-dystrobrevin and the extracellular matrix, established a Z-disc–ECM mechanical link and placed desmin in a broader sarcomeric scaffolding network alongside myopalladin.

   Evidence Reciprocal co-immunoprecipitation, yeast two-hybrid, immunoelectron microscopy at Z-lines; overexpression of myopalladin domains in cardiomyocytes disrupting desmin

   PMID:11309420 PMID:11353857

   Open questions at the time

   • Whether desmin–desmuslin interaction is regulated by post-translational modifications is unknown
   • Functional consequence of disrupting desmin–desmuslin interaction in vivo not tested
5. 2007 High

   Systematic comparison of DES mutations across all rod-domain segments showed that 2B-domain mutations cause the most severe network disruption while tail-domain mutations produce only mild effects, establishing domain-specific structure–function relationships for filament integrity.

   Evidence Transfection of multiple DES mutants into SW13 cells, smooth muscle cells, and neonatal rat cardiomyocytes with confocal microscopy

   PMID:17325244

   Open questions at the time

   • No atomic-resolution structural model of desmin filament to explain domain-specific severity
   • Long-term consequences in muscle tissue not assessed
6. 2010 High

   Identification of the de novo DES p.N116S mutation in the 1A rod segment as a cause of ARVC expanded the disease spectrum linked to desmin and demonstrated that 1A mutations also severely impair filament assembly, as quantified by viscosimetry and atomic force microscopy.

   Evidence Viscosimetry and AFM of recombinant desmin; SW13 cell transfection; immunohistochemistry of patient myocardium

   PMID:20829228

   Open questions at the time

   • Mechanism by which desmin aggregates promote arrhythmogenic remodeling not defined
   • Single-family evidence for ARVC link
7. 2019 High

   Co-transfection experiments with the p.Q113_L115del mutant demonstrated a dominant-negative mechanism whereby mutant desmin poisons wild-type filament assembly in the heterozygous state, directly explaining autosomal-dominant inheritance.

   Evidence Co-transfection of wild-type and mutant desmin in cells; confocal microscopy; patient myocardial immunohistochemistry

   PMID:30908796

   Open questions at the time

   • Stoichiometric threshold of mutant desmin needed for dominant-negative effect unknown
   • Whether all rod-domain mutations act through the same dominant-negative mechanism is untested
8. 2020 High

   Further 2B-domain variants (p.Ile402Thr, p.Glu410Lys) confirmed the pattern of filament assembly failure and aggregate formation, and linked DES mutations to conduction disease beyond cardiomyopathy, broadening the clinical genotype–phenotype correlation.

   Evidence Transfection in SW-13 and H9c2 cells; immunohistochemistry and electron microscopy of patient myocardium

   PMID:33373648

   Open questions at the time

   • Electrophysiological mechanism of conduction disease from desmin aggregates unexplained
9. 2021 High

   Multiple discoveries refined the DES disease model: a splice-site mechanism was shown to produce a truncated desmin causing restrictive cardiomyopathy, iPSC-cardiomyocyte models recapitulated aggregation from p.A337P, and epistatic regulation of desmin phosphorylation by PDE4DIP/PKA was identified as a modifier of arrhythmia penetrance.

   Evidence Nanopore amplicon sequencing and Western blot of patient tissue; iPSC-cardiomyocyte and SW-13 transfections; whole-exome sequencing with in vitro PKA phosphorylation assays

   PMID:33478057 PMID:34289528 PMID:34680517

   Open questions at the time

   • Specific PKA phosphosites on desmin and their functional consequences for filament dynamics not mapped systematically
   • PDE4DIP epistasis observed in a single family

• A high-resolution structural model of assembled desmin filaments is lacking, the mechanism by which desmin aggregates cause cardiomyocyte death and conduction defects remains undefined, and whether the dominant-negative paradigm applies uniformly across all pathogenic DES mutations is untested.
• No cryo-EM or crystal structure of full-length desmin filament
• Aggregate toxicity mechanism (proteotoxic stress, mechanical failure, or both) unresolved
• Comprehensive genotype–phenotype model across all DES mutation classes absent